about retatrutide Everything You Need To Know in 2026 (WATCH BEFORE TAKING) Retatrutide vs Tirzepatide (2026): Differences

Our goal is to make accessing treatments like and Retatrutide as straightforward as possible, helping you take the first step toward your health goals with confidence and support

Tirzepatide is a dual agonist targeting GLP-1R and GIPR Retatrutide adds GCGR activation as a third receptor target

At 6 months, there was no significant change in median body weight between groups (L:2.6 kg, P:2.9 kg, p = 0.92, Table 2)

The biggest shift was in frozen foods, where GLP-1 weight loss users monthly spending fell 3 points from their pre-use baseline during their first year on the drug

Exenatide extended-release: Once a week

Then, the FDA declared in late 2024 that tirzepatide was no longer in shortage, and it determined that semaglutide was no longer in shortage in early 2025